公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
2017 | Activity and safety of AZD3759 in EGFR-mutant non-small-cell lung cancer with CNS metastases (BLOOM): a phase 1, open-label, dose-escalation and dose-expansion study | Ahn M.-J; Kim D.-W; Cho B.C; Kim S.-W; Lee J.S; Ahn J.-S; Kim T.M; CHIA-CHI LIN ; Kim H.R; John T; Kao S; Goldman J.W; Su W.-C; Natale R; Rabbie S; Harrop B; Overend P; Yang Z; CHIH-HSIN YANG | The Lancet Respiratory Medicine | 81 | 67 | |
2016 | Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: Phase III randomized LUX-Lung 5 trial | Schuler M; CHIH-HSIN YANG ; Park K; Kim J.-H; Bennouna J; Chen Y.-M; Chouaid C; De Marinis F; Feng J.-F; Grossi F; Kim D.-W; Liu X; Lu S; Strausz J; Vinnyk Y; Wiewrodt R; Zhou C; Wang B; Chand V.K; Planchard D; Bagnes C; Martin C.M; Recondo G; Zarba J.J; Blajman C; Richardet M; McLachlan S.-A; Parente P; Underhill C; Crombie C; Mainwaring P; Greil R; Humblet Y; Bustin F; Carestia L; Galdermans D; Lambrechts M; Delval L; Vercauter P; Zhou C; Wang J; Huang C; Lin X; Wu Y; Liu X; Cheng Y; Qin S; Feng J; Huang J; Zhang Y; Lu S; Zereu M; Garicochea B; Zadra C.A; Riska H; Alanko T; Cadranel J; Chouaid C; Zalcman G; Sibilot D.M; Perol M; Planchard D; Bennouna J; Fournel P; Gervais R; Rotarski M; Coudert B; Thomas M; Wehler T; Faehling M; Keilholz U; Laack E; Von Pawel J; Huber R; Dickgreber N; Wiewrodt R; Mark Z; Tehenes S; Strausz J; Sarosi V; Prabhash K; Jain M; Venkatesan S; Sharma L; Dadhich H; Nagarkar R.V; Onn A; Gottfried M; Stemmer S; Migliorino M.R; Bidoli P; Bearz A; Gridelli C; Milandri C; Platania M; Ceresoli G.L; Cruciani G; Delgado F.G; Perez J.L.G; Luna G.A; Baca O.P; Aerts J; Stigt J; Dingemans A.-M; Herder G; Gans S; Sánchez J.F.S; Barreda R.L.A; Pantigoso W.R; Palomino O.L.M; Jaskiewicz P; Kazarnowicz A; Serwatowski P; Szczesna A; Jassem J; Lubennikov V; Karaseva N; Orlov S; Ragulin Y; Garrido P; Larriba J.L.G; Camps C; Campelo R.G; Lianes P; Cobo M; Felip E; Kim D.-W; Kim S.-W; Park K; Kim J.-H; Han J.-Y; Kim Y.-C; Yang C.-H; Hsia T.-C; Chen Y.-M; Tsai Y.-H; Chang G.-C; Tsao T.C.-Y; Su W.-C; Huang M.-S; Ho C.-L; Hsieh R.-K; Vinnyk Y; Popovych O; Ponomarova O; Bondarenko I; Polishchuk I; Shah R; Mitra S; Popat S; Spicer J; Toy E; Talbot T; Brown E; Upadhyay S; Summers Y; Gurtler J; Meza L; Thropay J; LUX-Lung 5 Investigators | Annals of Oncology | 118 | 110 | |
2016 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial | Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG ; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. | The Lancet Oncology | 936 | 827 | |
2017 | Afatinib versus gefitinib in patients with EGFR mutation-positive advanced non-small-cell lung cancer: Overall survival data from the phase IIb LUX-Lung 7 trial | Paz-Ares L; Tan E.-H; O'Byrne K; Zhang L; Hirsh V; Boyer M; CHIH-HSIN YANG ; Mok T; Lee K.H; Lu S; Shi Y; Lee D.H; Laskin J; Kim D.-W; Laurie S.A; Kölbeck K; Fan J; Dodd N; Märten A; Park K. | Annals of Oncology | 424 | 369 | |
2016 | AZD3759, a BBB-penetrating EGFR inhibitor for the treatment of EGFR mutant NSCLC with CNS metastases | Yang Z; Guo Q; Wang Y; Chen K; Zhang L; Cheng Z; Xu Y; Yin X; Bai Y; Rabbie S; Kim D.-W; Ahn M.-J; CHIH-HSIN YANG ; Zhang X. | Science Translational Medicine | 82 | 28 | |
2015 | AZD9291 in EGFR inhibitor-resistant non-small-cell lung cancer | Jänne P.A; Chih-Hsin CHIH-HSIN YANG ; Kim D.-W; Planchard D; Ohe Y; Ramalingam S.S; Ahn M.-J; Kim S.-W; Su W.-C; Horn L; Haggstrom D; Felip E; Kim J.-H; Frewer P; Cantarini M; Brown K.H; Dickinson P.A; Ghiorghiu S; Ranson M. | New England Journal of Medicine | 1749 | 1621 | |
2018 | Brigatinib versus crizotinib in ALK-positive non-small-cell lung cancer | Camidge D.R; Kim H.R; Ahn M.-J; CHIH-HSIN YANG ; Han J.-Y; Lee J.-S; Hochmair M.J; Li J.Y.-C; Chang G.-C; Lee K.H; Gridelli C; Delmonte A; Garcia Campelo R; Kim D.-W; Bearz A; Griesinger F; Morabito A; Felip E; Califano R; Ghosh S; Spira A; Gettinger S.N; Tiseo M; Gupta N; Haney J; Kerstein D; Popat S. | New England Journal of Medicine | 688 | 556 | |
2018 | Cumulative incidence rates for CNS and non-CNS progression in two phase II studies of alectinib in ALK-positive NSCLC | Gadgeel S; Shaw A.T; Barlesi F; Crinò L; CHIH-HSIN YANG ; Dingemans A.-M.C; Kim D.-W; De Marinis F; Schulz M; Liu S; Gupta R; Kotb A; Ou S.-H.I. | British Journal of Cancer | 21 | 21 | |
2018 | Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study | Garassino M.C; Cho B.-C; Kim J.-H; Mazières J; Vansteenkiste J; Lena H; Corral Jaime J; Gray J.E; Powderly J; Chouaid C; Bidoli P; Wheatley-Price P; Park K; Soo R.A; Huang Y; Wadsworth C; Dennis P.A; Rizvi N.A; Paz-Ares Rodriguez L; Novello S; Hiret S; Schmid P; Laack E; Califano R; Maemondo M; Kim S.-W; Chaft J; Vicente Baz D; Berghmans T; Kim D.-W; Surmont V; Reck M; Han J.-Y; Holgado Martin E; Belda Iniesta C; Oe Y; Chella A; Chopra A; Robinet G; Soto Parra H; Thomas M; Cheema P; Katakami N; Su W.-C; Kim Y.-C; Wolf J; Lee J.-S; Saka H; Milella M; Ramos Garcia I; Sibille A; Yokoi T; Kang E.J; Atagi S; Spaeth-Schwalbe E; Nishio M; Imamura F; Gabrail N; Veillon R; Derijcke S; Maeda T; Zylla D; Kubiak K; Santoro A; Uy M.N; Lucien Geater S; Italiano A; Kowalski D; Barlesi F; Chen Y.-M; Spigel D; Chewaskulyong B; Garcia Gomez R; Alvarez Alvarez R; CHIH-HSIN YANG ; Hsia T.-C; Denis F; Sakai H; Vincent M; Goto K; Bosch-Barrera J; Weiss G; Canon J.-L; Scholz C; Aglietta M; Kemmotsu H; Azuma K; Bradbury P; Feld R; Chachoua A; Jassem J; Juergens R; Palmero Sanchez R; Malcolm A; Vrindavanam N; Kubota K; Waller C; Waterhouse D; Coudert B; Mark Z; Satouchi M; Chang G.-C; Herzmann C; Chaudhry A; Giridharan S; Hesketh P; Ikeda N; Boccia R; Iannotti N; Haigentz M; Reynolds J; Querol J; Nakagawa K; Sugawara S; Tan E.H; Hirashima T; Gettinger S; Kato T; Takeda K; Juan Vidal O; Mohn-Staudner A; Panwalkar A; Daniel D; Kobayashi K; Ladrera G.E.I; Schulte C; Sebastian M; Cernovska M; Coupkova H; Havel L; Pauk N; Singh J; Murakami S; Csoszi T; Losonczy G; Price A; Anderson I; Iqbal M; Torri V; Juhasz E; Khanani S; Koubkova L; Levy B; Page R; Bocskei C; Crinò L; Einspahr D; Hagenstad C; Juat N; Overton L; Garrison M; Szalai Z; ATLANTIC Investigators | The Lancet Oncology | 468 | 397 | |
2017 | Efficacy of alectinib in central nervous system metastases in crizotinib-resistant ALK-positive non–small-cell lung cancer: Comparison of RECIST 1.1 and RANO-HGG criteria | Gandhi L; Ignatius Ou S.-H; Shaw A.T; Barlesi F; Dingemans A.-M.C; Kim D.-W; Camidge D.R; Hughes B.G.M; CHIH-HSIN YANG ; de Castro J; Crino L; Léna H; Do P; Golding S; Bordogna W; Zeaiter A; Kotb A; Gadgeel S. | European Journal of Cancer | 27 | 24 | |
2019 | First-line afatinib vs gefitinib for patients with EGFR mutation-positive NSCLC (LUX-Lung 7): impact of afatinib dose adjustment and analysis of mode of initial progression for patients who continued treatment beyond progression | Schuler M; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG ; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Massey D; Märten A; Paz-Ares L; Park K. | Journal of Cancer Research and Clinical Oncology | 29 | 27 | |
2016 | LBA1_PR: Osimertinib as first-line treatment for EGFR mutation-positive advanced NSCLC: updated efficacy and safety results from two Phase I expansion cohorts | Ramalingam S; CHIH-HSIN YANG ; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Jänne P.A. | Journal of Thoracic Oncology | 66 | 57 | |
2018 | Osimertinib as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer | Ramalingam S.S; CHIH-HSIN YANG ; Lee C.K; Kurata T; Kim D.-W; John T; Nogami N; Ohe Y; Mann H; Rukazenkov Y; Ghiorghiu S; Stetson D; Markovets A; Barrett J.C; Thress K.S; Jänne P.A. | Journal of Clinical Oncology | 401 | 346 | |
2019 | Osimertinib Plus Durvalumab versus Osimertinib Monotherapy in EGFR T790M–Positive NSCLC following Previous EGFR TKI Therapy: CAURAL Brief Report | Chih-Hsin CHIH-HSIN YANG ; Shepherd F.A; Kim D.-W; Lee G.-W; Lee J.S; Chang G.-C; Lee S.S; Wei Y.-F; Lee Y.G; Laus G; Collins B; Pisetzky F; Horn L. | Journal of Thoracic Oncology | 148 | 126 | |
2019 | Pan-asian adapted clinical practice guidelines for the management of patients with metastatic non-small-cell lung cancer: A csco-esmo initiative endorsed by jsmo, ksmo, mos, sso and tos | Wu Y.-L; Planchard D; Lu S; Sun H; Yamamoto N; Kim D.-W; Tan D.S.W; CHIH-HSIN YANG ; Azrif M; Mitsudomi T; Park K; Soo R.A; Chang J.W.C; Alip A; Peters S; Douillard J.-Y. | Annals of Oncology | 209 | 174 | |
2018 | Phase Ib/II Study of Capmatinib (INC280) Plus Gefitinib after Failure of Epidermal Growth Factor Receptor (EGFR) Inhibitor Therapy in Patients with EGFR-Mutated, MET Factor-Dysregulated Non-Small-Cell Lung Cancer | Wu Y.-L; Zhang L; Kim D.-W; Liu X; Lee D.H; CHIH-HSIN YANG ; Ahn M.-J; Vansteenkiste J.F; Su W.-C; Felip E; Chia V; Glaser S; Pultar P; Zhao S; Peng B; Akimov M; Tan D.S.W. | Journal of Clinical Oncology | 245 | 211 | |
2018 | Phase II study of crizotinib in east asian patients with ROS1-positive advanced non–small-cell lung cancer | Wu Y.-L; CHIH-HSIN YANG ; Kim D.-W; Lu S; Zhou J; Seto T; Yang J.-J; Yamamoto N; Ahn M.-J; Takahashi T; Yamanaka T; Kemner A; Roychowdhury D; Paolini J; Usari T; Wilner K.D; Goto K. | Journal of Clinical Oncology | 228 | 183 | |
2016 | Pooled analysis of CNS response to alectinib in two studies of pretreated patients with ALK-positive non-small-cell lung cancer | Gadgeel S.M; Shaw A.T; Govindan R; Gandhi L; Socinski M.A; Camidge D.R; De Petris L; Kim D.-W; Chiappori A; Moro-Sibilot D.L; Duruisseaux M; Crino L; De Pas T; Dansin E; Tessmer A; CHIH-HSIN YANG ; Han J.-Y; Bordogna W; Golding S; Zeaiter A; Ou S.-H.I. | Journal of Clinical Oncology | 163 | 142 | |
2020 | Pooled overall survival and safety data from the pivotal phase II studies (NP28673 and NP28761) of alectinib in ALK-positive non-small-cell lung cancer | Ou S.-H.I; Gadgeel S.M; Barlesi F; CHIH-HSIN YANG ; De Petris L; Kim D.-W; Govindan R; Dingemans A.-M; Crino L; Léna H; Popat S; Ahn J.S; Dansin E; Mitry E; Müller B; Bordogna W; Balas B; Morcos P.N; Shaw A.T. | Lung Cancer | 23 | 10 | |
2017 | Pooled Systemic Efficacy and Safety Data from the Pivotal Phase II Studies (NP28673 and NP28761) of Alectinib in ALK-positive Non-Small Cell Lung Cancer | CHIH-HSIN YANG ; Ou S.-H.I; De Petris L; Gadgeel S; Gandhi L; Kim D.-W; Barlesi F; Govindan R; Dingemans A.-M.C; Crino L; Lena H; Popat S; Ahn J.S; Dansin E; Golding S; Bordogna W; Balas B; Morcos P.N; Zeaiter A; Shaw A.T. | Journal of Thoracic Oncology | 75 | 56 | |